Vi­a­tris plans for Ozem­pic, We­govy gener­ics amid law­suit from No­vo Nordisk over We­govy

Vi­a­tris Phar­ma­ceu­ti­cals’ ap­pli­ca­tions for gener­ic op­tions for type 2 di­a­betes drug Ozem­pic and weight loss drug We­govy are now un­der reg­u­la­to­ry re­view, ac­cord­ing to the com­pa­ny’s sec­ond quar­ter pre­sen­ta­tion.

If ap­proved, both would be the first gener­ics to mar­ket for the block­buster drugs.

But No­vo Nordisk has al­ready tak­en steps to stop Vi­a­tris from bring­ing a We­govy gener­ic to mar­ket with a law­suit filed in Jan­u­ary in Delaware Dis­trict Court. In court fil­ings, lawyers for No­vo wrote that the law­suit comes from Vi­a­tris’ sub­mis­sion of an ab­bre­vi­at­ed NDA to the FDA for a We­govy gener­ic in­jec­tion pri­or to the patents’ ex­pi­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER